View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Transzplantációs és Sebészeti Klinika Budapest
  • | 2 Semmelweis Egyetem, Általános Orvostudományi Kar III. Belgyógyászati Klinika Budapest
Open access

Cross Mark

A transzplantációs immunológia kiemelt fontosságú területe az antitestmediált rejectio elleni küzdelem, amelynek hátterében a graft által prezentált humán leukocytaantigének ellen képződő antitestek állnak. A szilárd fázisú immunológiai tesztek bevezetésével jelentősen megváltozott az antitestek monitorozásának gyakorlata, aminek jelentősége van a transzplantációt megelőzően és azt követően is. Ennek ellenére hiányosak az ismeretek a teszt során detektált antitestek klinikai relevanciáját tekintve, ezenfelül technikai kihívások és a betegellátás során alkalmazott különböző stratégiák színesítik a képet. A szerzők a transzplantációs antitestmonitorozás laboratóriumi módszereinek egységesítésére vonatkozó ajánlásokat és a vesetranszplantált betegek ellátásában javasolt algoritmusokat mutatják be összefoglaló közleményükben. A szilárd fázisú technikák kombinálása a komplementaktiváció kimutatásával ígéretes eszköznek mutatkozik. A komplementkötő antitestek kimutatásán alapuló módszerek fontos kérdésekre adhatnak választ a detektált antitestek klinikai relevanciáját illetően. Az új módszerek alkalmazása során felmerülő kérdések megválaszolása és az ajánlások ismerete szükséges ahhoz, hogy ezen a dinamikusan fejlődő területen naprakészek maradjunk. Orv. Hetil., 2014, 155(46), 1820–1830.

  • Süsal, C., Roelen, D. L., Fischer, G., et al.: Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antigens, 2013, 82(2), 83–92.

  • Tait, B. D., Süsal, C., Gebel, H. M., et al.: Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation, 2013, 95(1), 19–47.

  • Halloran, P. F., Wadgymar, A., Ritchie, S., et al.: The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation, 1990, 49(1), 85–91.

  • Halloran, P. F., Schlaut, J., Solez, K., et al.: The significance of the anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation, 1992, 53(3), 550–555.

  • Regele, H., Exner, M., Watschinger, B., et al.: Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol. Dial. Transplant., 2001, 16(10), 2058–2066.

  • Feucht, H. E., Schneeberger, H., Hillebrand, G., et al.: Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int., 1993, 43(6), 1333–1338.

  • Feucht, H. E., Felber, E., Gokel, M. J., et al.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol., 1991, 86(3), 464–470.

  • Racusen, L. C., Haas, M.: Antibody-mediated rejection in renal allografts: lessons from pathology. Clin. J. Am. Soc. Nephrol., 2006, 1(3), 415–420.

  • Crespo, M., Pascual, M., Tolkoff-Rubin, N., et al.: I. Acute humoral rejection in renal allograft recipients: Incidence, serology, and clinical characteristics. Transplantation, 2001, 71(5), 652–658.

  • Einecke, G., Sis, B., Reeve, J., et al.: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant., 2009, 9(11), 2520–2531.

  • Wiebe, C., Gibson, I. W., Blydt-Hansen, T. D., et al.: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant., 2012, 12(5), 1157–1167.

  • Cai, J., Terasaki, P. I.: Human leukocyte antigen antibodies for monitoring transplant patients. Surg. Today, 2005, 35(8), 605–612.

  • Cai, J., Terasaki, P. I.: Humoral theory of transplantation: mechanism, prevention, and treatment. Hum. Immunol., 2005, 66(4), 334–342.

  • Everly, M. J., Rebellato, L. M., Haisch, C. E., et al.: Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation, 2013, 95(3), 410–417.

  • Lachmann, N., Terasaki, P. I., Budde, K., et al.: Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation, 2009, 87(10), 1505–1513.

  • Hansen, R., Seifeldin, R., Noe, L.: Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant. Proc., 2007, 39(5), 1287–1300.

  • Opelz, G., Döhler, B.: Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation, 2008, 86(3), 371–376.

  • 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999–2008. http://www.ustransplant.org/annual_reports/current/

  • Fuggle, S. V., Martin, S.: Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation, 2008, 86(3), 384–390.

  • Eurotransplant International Foundation Annual Report 2010. Arie Oosterlee and Axel Rahmel. Central Office. Leiden, http://www.eurotransplant.org/cms/index.php?page=annual_reports

  • Cosio, F. G., Alamir, A., Yim, S., et al.: Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int., 1998, 53(3), 767–772.

  • Remport, A., Keszei, A., Vamos, E. P., et al.: Association of pre-transplant dialysis duration with outcome in kidney transplant recipients: a prevalent cohort study. Int. Urol. Nephrol,. 2011, 43(1), 215–224.

  • Opelz, G., Collaborative Transplant Study: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet, 2005, 365(9470), 1570–1576.

  • Morath, C., Opelz, G., Zeier, M., et al.: Prevention of antibody-mediated kidney transplant rejection. Transpl. Int., 2012, 25(6), 633–645.

  • Collaborative Transplant Study http://www.ctstransplant.org.

  • Süsal, C., Döhler, B., Opelz, G.: Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum. Immunol., 2009, 70(8), 569–573.

  • Doxiadis, I. I., Smits, J. M., Persijn, G. G., et al.: It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation, 2004, 77(4), 615–617.

  • De Meester, J., Doxiadis, I. I., Persijn, G. G., et al.: Renal transplantation of highly sensitised patients via prioritised renal allocation programs. Shorter waiting time and above-average graft survival. Nephron, 2002, 92(1), 111–119.

  • Claas, F. H., Witvliet, M. D., Duquesnoy, R. J., et al.: The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation, 2004, 78(2), 190–193.

  • Morath, C., Opelz, G., Zeier, M., et al.: Kidney transplantation for high-risk sensitized patients – the „Heidelberg algorithm”. Transplant. Proc., 2011, 43(3), 801–804.

  • Wahrmann, M., Haidinger, M., Körmöczi, G. F., et al.: Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation, 2010, 89(11), 1385–1390.

  • Montgomery, R. A., Lonze, B. E., King, K. E., et al.: Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med., 2011, 365(4), 318–326.

  • Patel, R., Terasaki, P. I.: Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med., 1969, 280(14), 735–739.

  • Gombos, P., Opelz, G., Scherer, S., et al.: Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am. J. Transplant., 2013, 13(8), 2075–2082.

  • Gupta, A., Iveson, V., Varagunam, M., et al.: Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation, 2008, 85(8), 1200–1204.

  • Süsal, C., Ovens, J., Mahmoud, K., et al.: No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation, 2011, 91(8), 883–887.

  • Van den Berg-Loonen, E. M., Billen, E. V., Voorter, C. E., et al.: Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation, 2008, 85(8), 1086–1090.

  • Wolfe, R. A., Ashby, V. B., Milford, E. L., et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med., 1999, 341(23), 1725–1730.

  • Zachary, A. A., Montgomery, R. A., Leffell, M. S.: Defining unacceptable HLA antigens. Curr. Opin. Organ. Transplant., 2008, 13(4), 405–410.

  • Tillou, X., Poirier, N., Le Bas-Bernardet, S., et al.: Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int., 2010, 78(2), 152–159.

  • Chen, G., Sequeira, F., Tyan, D. B.: Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum. Immunol., 2011, 72(10), 849–858.

  • Lachmann, N., Todorova, K., Schulze, H., et al.: Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation, 2013, 95(5), 694–700.

  • Wahrmann, M., Exner, M., Regele, H., et al.: Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J. Immunol. Methods, 2003, 275(1–2), 149–160.

  • Wahrmann, M., Exner, M., Schillinger, M., et al.: Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am. J. Transplant., 2006, 6(5 Pt 1), 1033–1041.

  • Tyan, D. B.: New approaches for detecting complement-fixing antibodies. Curr. Opin. Organ. Transplant., 2012, 17(4), 409–415.

  • Chin, C., Chen, G., Sequeria, F., et al.: Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant., 2011, 30(2), 158–163.

  • Loupy, A., Lefaucheur, C., Vernerey, D., et al.: Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med., 2013, 369(13), 1215–1226.

  • Yabu, J. M., Higgins, J. P., Chen, G., et al.: C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation, 2011, 91(3), 342–347.

  • Terasaki, P. I.: Humoral theory of transplantation. Am. J. Transplant., 2003, 3(6), 665–673.

  • Lefaucheur, C., Nochy, D., Andrade, J., et al.: Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am. J. Transplant., 2009, 9(5), 1099–1107.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 49 46 1
PDF Downloads 95 93 7